AGenome-Wide Association Study ofMyasthenia Gravis

Alan E. Renton, PhD; Hannah A. Pliner, BS; Carlo Provenzano, MD, PhD; Amelia Evoli, MD; Roberta Ricciardi, MD; Michael A. Nalls, PhD; Giuseppe Marangi, MD; Yevgeniya Abramzon; Sampath Arepalli, MS; Sean Chong, BS; Dena G. Hernandez, MS; Janel O. Johnson, PhD; Emanuela Bartoccioni, PhD; Flavia Scuderi; Michelangelo Maestri, MD; J. Raphael Gibbs, MS; Edoardo Errichiello; Adriano Chiò, MD; Gabriella Restagno, MD; Mario Sabatelli, MD; Mark Macek, MS; Sonja W. Scholz, MD, PhD; Andrea Corse, MD; Vinay Chaudhry, MD; Michael Benatar, MD, PhD; Richard J. Barohn, MD; April McVey, MD; Mamatha Pasnoor, MD; Mazen M. Dimachkie, MD; Julie Rowin, MD; John Kissel, MD; Miriam Freimer, MD; Henry J. Kaminski, MD; Donald B. Sanders, MD; Bernadette Lipscomb, RN; Janice M. Massey, MD; Manisha Chopra, MD; James F. Howard Jr, MD; Wilma J. Koopman, RN; Michael W. Nicolle, MD; Robert M. Pascuzzi, MD; Alan Pestronk, MD; Charlie Wulf; Julaine Florence, PhD; Derrick Blackmore, BSc; Aimee Soloway, RN; Zaeem Siddiqi, MD; Srikanth Muppidi, MD; Gil Wolfe, MD; David Richman, MD; Michelle M. Mezei, MD; Theresa Jiwa; Joel Oger, MD; Daniel B. Drachman, MD; Bryan J. Traynor, MD, PhD

[1]  M. Nalls,et al.  Genome-wide analysis of the heritability of amyotrophic lateral sclerosis. , 2014, JAMA neurology.

[2]  R. Lewis,et al.  Autoantibodies to Agrin in Myasthenia Gravis Patients , 2014, PloS one.

[3]  Mohamad Saad,et al.  Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. , 2013, Human molecular genetics.

[4]  Soumya Raychaudhuri,et al.  Risk for myasthenia gravis maps to a 151Pro→Ala change in TNIP1 and to human leukocyte antigen‐B*08 , 2012, Annals of neurology.

[5]  R. Mantegazza,et al.  Autoimmune mechanisms in myasthenia gravis. , 2012, Current opinion in neurology.

[6]  L. Liang,et al.  A genome-wide association study identifies two new risk loci for Graves' disease , 2011, Nature Genetics.

[7]  G. Anderson,et al.  Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 , 2011, Science.

[8]  P. Visscher,et al.  Estimating missing heritability for disease from genome-wide association studies. , 2011, American journal of human genetics.

[9]  Y. Yamanashi,et al.  Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis , 2011, Annals of neurology.

[10]  A. Sanchez‐Mazas,et al.  HLA DNA Sequence Variation among Human Populations: Molecular Signatures of Demographic and Selective Events , 2011, PloS one.

[11]  V. Krishnamurthi A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) , 2010 .

[12]  J. Nutt,et al.  Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease , 2010, Nature Genetics.

[13]  P. Visscher,et al.  Common SNPs explain a large proportion of the heritability for human height , 2010, Nature Genetics.

[14]  C. Cardwell,et al.  A systematic review of population based epidemiological studies in Myasthenia Gravis , 2010, BMC neurology.

[15]  P. Deloukas,et al.  Multiple common variants for celiac disease influencing immune gene expression , 2010, Nature Genetics.

[16]  Larry W. Moreland,et al.  REL, a member of the NF-κB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis , 2009, Nature Genetics.

[17]  D. Clayton,et al.  Genome-wide association study and meta-analysis finds over 40 loci affect risk of type 1 diabetes , 2009, Nature Genetics.

[18]  A. Alshekhlee,et al.  Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals , 2009, Neurology.

[19]  David Mellis,et al.  Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. , 2008, American journal of human genetics.

[20]  J. Aarli Myasthenia Gravis in the Elderly , 2008, Annals of the New York Academy of Sciences.

[21]  M. Daly,et al.  Estimation of the multiple testing burden for genomewide association studies of nearly all common variants , 2008, Genetic epidemiology.

[22]  R. Pirskanen,et al.  Two SNPs in the promoter region of the CTLA‐4 gene affect binding of transcription factors and are associated with human myasthenia gravis , 2007, Journal of internal medicine.

[23]  M. Dougados,et al.  Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate , 2007, Annals of the rheumatic diseases.

[24]  K. Chan,et al.  Frequency of seronegativity in adult‐acquired generalized myasthenia gravis , 2007, Muscle & nerve.

[25]  R. Lisak,et al.  Myasthenic crisis: Guidelines for prevention and treatment , 2007, Journal of the Neurological Sciences.

[26]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[27]  Paul Garside,et al.  Reversal of the TCR Stop Signal by CTLA-4 , 2006, Science.

[28]  S. Gabriel,et al.  Assessing the impact of population stratification on genetic association studies , 2004, Nature Genetics.

[29]  P. Tonali,et al.  Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. , 2003, Brain : a journal of neurology.

[30]  A. Vincent,et al.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies , 2001, Nature Medicine.

[31]  J. Mendell,et al.  Myasthenia Gravis and Associated Autoimmune Diseases in Children , 2000, Journal of child neurology.

[32]  E. Stålberg,et al.  SFEMG in ocular myasthenia gravis diagnosis , 2000, Clinical Neurophysiology.

[33]  W. Dougall,et al.  RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.

[34]  P. Linsley,et al.  Immunotherapy of experimental autoimmune myasthenia gravis: selective effects of CTLA4Ig and synergistic combination with an IL2-Diphtheria toxin fusion protein , 1998, Journal of Neuroimmunology.

[35]  P. Szabo,et al.  Effect of age on humoral immunity, selection of the B‐cell repertoire and B‐cell development , 1997, Immunological reviews.

[36]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[37]  H. Garchon,et al.  Association of the AChRalpha-subunit gene (CHRNA), DQA1*0101, and the DR3 haplotype in myasthenia gravis. Evidence for a three-gene disease model in a subgroup of patients. , 1997, Journal of autoimmunity.

[38]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[39]  P. Linsley,et al.  Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis. , 1995, Cellular immunology.

[40]  I. Tsiropoulos,et al.  Associated autoimmune diseases in myasthenia gravis A population‐based study , 1995, Acta neurologica Scandinavica.

[41]  J. Weber,et al.  Genetic linkage of familial expansile osteolysis to chromosome 18q. , 1994, Human molecular genetics.

[42]  R. Lovelace,et al.  Seronegative myasthenia gravis , 1988, Neurology.

[43]  R. Pirskanen GENETIC ASPECTS IN MYASTHENIA GRAVIS , 1977, Acta neurologica Scandinavica.

[44]  D. Elmqvist Myasthenia Gravis , 1975, The Lancet.

[45]  D. Grob,et al.  Familial myasthenia gravis. Report of 27 patients in 12 families and review of 164 patients in 73 families. , 1971, Archives of neurology.

[46]  Simon C. Potter,et al.  Using genome-wide complex trait analysis to quantify ‘ missing heritability ’ in Parkinson ’ s disease , 2012 .

[47]  W. G. Hill,et al.  Genome partitioning of genetic variation for complex traits using common SNPs , 2011, Nature Genetics.

[48]  Peter Dalgaard,et al.  R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .

[49]  G. Abecasis,et al.  Genotype imputation. , 2009, Annual review of genomics and human genetics.

[50]  R. Pirskanen,et al.  Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis , 2005, Immunogenetics.

[51]  A. Szobor Myasthenia gravis: familial occurrence. A study of 1100 myasthenia gravis patients. , 1989, Acta medica Hungarica.